Literature DB >> 396335

Opsonic specificity of human antibody to the type III polysaccharide of group B Streptococcus.

M S Edwards, C J Baker, D L Kasper.   

Abstract

The functional significance of vaccine-induced or naturally acquired antibody to the capsular polysaccharide of type III group B Streptococcus was determined in human sera by means of an opsonophagocytic assay. Sera containing a sufficient concentration of type-specific antibody and endogenous serum complement caused a significant reduction (greater than 1 log10) in colony-forming units for each of 22 type III clinical isolates after incubation for 40 min. In contrast, serum with a very low concentration of antibody (0.4 micrograms/ml) killed only one isolate. Absorption of serum containing vaccine-induced antibody with purified native type III polysaccharide decreased opsonophagocytosis by a mean of 1.2 log10 for 11 selected type III strains. These results indicate a lack of major antigenic differences among a wide spectrum of type III strains, since bactericidal activity of human serum is uniformly observed in the presence of complement and sufficient concentrations of antibody to the type III polysaccharide.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 396335     DOI: 10.1093/infdis/140.6.1004

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  34 in total

1.  Nonopsonic binding of type III Group B Streptococci to human neutrophils induces interleukin-8 release mediated by the p38 mitogen-activated protein kinase pathway.

Authors:  E A Albanyan; J G Vallejo; C W Smith; M S Edwards
Journal:  Infect Immun       Date:  2000-04       Impact factor: 3.441

2.  Deposition and degradation of C3 on type III group B streptococci.

Authors:  J R Campbell; C J Baker; M S Edwards
Journal:  Infect Immun       Date:  1991-06       Impact factor: 3.441

3.  Transposon mutagenesis of type III group B Streptococcus: correlation of capsule expression with virulence.

Authors:  C E Rubens; M R Wessels; L M Heggen; D L Kasper
Journal:  Proc Natl Acad Sci U S A       Date:  1987-10       Impact factor: 11.205

4.  Lectin site interaction with capsular polysaccharide mediates nonimmune phagocytosis of type III group B streptococci.

Authors:  E A Albanyan; M S Edwards
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

5.  Characterization of anticapsular monoclonal antibodies that regulate activation of the complement system by the Cryptococcus neoformans capsule.

Authors:  T R Kozel; B C deJong; M M Grinsell; R S MacGill; K K Wall
Journal:  Infect Immun       Date:  1998-04       Impact factor: 3.441

6.  Characterization of invasive group B streptococcus strains from the greater Toronto area, Canada.

Authors:  Sarah Teatero; Allison McGeer; Donald E Low; Aimin Li; Walter Demczuk; Irene Martin; Nahuel Fittipaldi
Journal:  J Clin Microbiol       Date:  2014-02-19       Impact factor: 5.948

7.  Neonatal mouse protection against infection with multiple group B streptococcal (GBS) serotypes by maternal immunization with a tetravalent GBS polysaccharide-tetanus toxoid conjugate vaccine.

Authors:  L C Paoletti; M R Wessels; A K Rodewald; A A Shroff; H J Jennings; D L Kasper
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

8.  Estimation of group B streptococcus type III polysaccharide-specific antibody concentrations in human sera is antigen dependent.

Authors:  R Bhushan; B F Anthony; C E Frasch
Journal:  Infect Immun       Date:  1998-12       Impact factor: 3.441

9.  Opsonin-independent phagocytosis of group B streptococci: role of complement receptor type three.

Authors:  J M Antal; J V Cunningham; K J Goodrum
Journal:  Infect Immun       Date:  1992-03       Impact factor: 3.441

10.  Alpha C protein-specific immunity in humans with group B streptococcal colonization and invasive disease.

Authors:  Pia S Pannaraj; Joanna K Kelly; Marcia A Rench; Lawrence C Madoff; Morven S Edwards; Carol J Baker
Journal:  Vaccine       Date:  2007-12-03       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.